IL126199A - Pharmaceutical preparation for administration through the nose for preventive treatment for delayed vomiting - Google Patents
Pharmaceutical preparation for administration through the nose for preventive treatment for delayed vomitingInfo
- Publication number
- IL126199A IL126199A IL12619997A IL12619997A IL126199A IL 126199 A IL126199 A IL 126199A IL 12619997 A IL12619997 A IL 12619997A IL 12619997 A IL12619997 A IL 12619997A IL 126199 A IL126199 A IL 126199A
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical composition
- composition according
- daily dosage
- hours
- metoclopramide
- Prior art date
Links
- 206010047700 Vomiting Diseases 0.000 title claims abstract description 60
- 230000003111 delayed effect Effects 0.000 title claims abstract description 47
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 41
- 238000011321 prophylaxis Methods 0.000 title claims description 18
- 239000007922 nasal spray Substances 0.000 claims abstract description 40
- 229940097496 nasal spray Drugs 0.000 claims abstract description 40
- 229960004503 metoclopramide Drugs 0.000 claims abstract description 21
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 claims abstract description 21
- 238000002512 chemotherapy Methods 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 22
- 238000009472 formulation Methods 0.000 claims description 19
- 239000002552 dosage form Substances 0.000 claims description 17
- 229960004316 cisplatin Drugs 0.000 claims description 16
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 16
- -1 belomycin Chemical compound 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- 229960004397 cyclophosphamide Drugs 0.000 claims description 3
- 229940127089 cytotoxic agent Drugs 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- 229960004528 vincristine Drugs 0.000 claims description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 3
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 229960005420 etoposide Drugs 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 229960003048 vinblastine Drugs 0.000 claims description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 2
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000008673 vomiting Effects 0.000 description 14
- 206010028813 Nausea Diseases 0.000 description 13
- 230000008693 nausea Effects 0.000 description 13
- 230000001154 acute effect Effects 0.000 description 10
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000002895 emetic Substances 0.000 description 8
- 230000000095 emetic effect Effects 0.000 description 8
- 229960003957 dexamethasone Drugs 0.000 description 7
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 7
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- 206010038776 Retching Diseases 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 3
- 235000019445 benzyl alcohol Nutrition 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 206010013710 Drug interaction Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 208000032140 Sleepiness Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 238000009104 chemotherapy regimen Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000006207 intravenous dosage form Substances 0.000 description 2
- IRQVJPHZDYMXNW-UHFFFAOYSA-N metoclopramide dihydrochloride monohydrate Chemical compound O.[Cl-].[Cl-].CC[NH+](CC)CCNC(=O)C1=CC(Cl)=C([NH3+])C=C1OC IRQVJPHZDYMXNW-UHFFFAOYSA-N 0.000 description 2
- 229960000923 metoclopramide hydrochloride Drugs 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 230000037321 sleepiness Effects 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000027776 Extrapyramidal disease Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000001062 anti-nausea Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000006204 intramuscular dosage form Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000006203 subcutaneous dosage form Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/616,121 US5760086A (en) | 1996-03-14 | 1996-03-14 | Nasal administration of agents for treatment of delayed onset emesis |
| PCT/US1997/003974 WO1997033573A1 (en) | 1996-03-14 | 1997-03-13 | Nasal administration of agents for treatment of delayed onset emesis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL126199A0 IL126199A0 (en) | 1999-05-09 |
| IL126199A true IL126199A (en) | 2004-06-01 |
Family
ID=24468120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12619997A IL126199A (en) | 1996-03-14 | 1997-03-13 | Pharmaceutical preparation for administration through the nose for preventive treatment for delayed vomiting |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US5760086A (cs) |
| EP (1) | EP0891186B1 (cs) |
| JP (1) | JP2000507234A (cs) |
| KR (1) | KR100420673B1 (cs) |
| CN (1) | CN1217657A (cs) |
| AT (1) | ATE489137T1 (cs) |
| AU (1) | AU707467B2 (cs) |
| BG (1) | BG102780A (cs) |
| CA (1) | CA2248968C (cs) |
| CZ (1) | CZ289797B6 (cs) |
| DE (1) | DE69740060D1 (cs) |
| DK (1) | DK0891186T3 (cs) |
| EE (1) | EE03665B1 (cs) |
| ES (1) | ES2357520T3 (cs) |
| IL (1) | IL126199A (cs) |
| NO (1) | NO984245L (cs) |
| NZ (1) | NZ331991A (cs) |
| PL (1) | PL328940A1 (cs) |
| PT (1) | PT891186E (cs) |
| RU (1) | RU2181588C2 (cs) |
| SK (1) | SK282695B6 (cs) |
| UA (1) | UA57733C2 (cs) |
| WO (1) | WO1997033573A1 (cs) |
| YU (1) | YU40398A (cs) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6770262B2 (en) | 2000-03-30 | 2004-08-03 | Questcor Pharmaceuticals, Inc. | Nasal administration of agents for the treatment of gastroparesis |
| RU2344813C1 (ru) * | 2007-04-26 | 2009-01-27 | Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по здравоохранению и социальному развитию | Способ предупреждения послеоперационной тошноты и рвоты у детей |
| EA019809B9 (ru) * | 2008-11-11 | 2014-08-29 | Юнилевер Нв | Композиция черного чая |
| PL2376075T3 (pl) * | 2008-12-22 | 2015-08-31 | Evoke Pharma Inc | Donosowe preparaty z metoklopramidu |
| US20130213393A1 (en) | 2009-12-22 | 2013-08-22 | Evoke Pharma, Inc. | Nasal formulations of metoclopramide |
| US20110165143A1 (en) * | 2010-01-06 | 2011-07-07 | The Regents Of The University Of Colorado, A Body Corporate | Modulation of caspases and therapeutical applications |
| TR201811221T4 (tr) | 2011-08-25 | 2018-08-27 | Evoke Pharma Inc | Dişi gastroparezi ile ilişkili semptomların tedavisi. |
| FR2980976B1 (fr) | 2011-10-10 | 2015-10-16 | Mohamed Skiba | Composition pharmaceutique pour l'administration par voie nasale de la metopimazine |
| CN104606136A (zh) * | 2015-01-06 | 2015-05-13 | 中国人民解放军军事医学科学院毒物药物研究所 | 甲氧氯普胺鼻腔喷雾剂、其制备方法及用途 |
| CA3047088A1 (en) | 2016-12-15 | 2018-06-21 | Evoke Pharma, Inc. | Treatment of moderate and severe gastroparesis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8412585D0 (en) * | 1984-05-17 | 1984-06-20 | Beecham Group Plc | Composition |
| US4624965A (en) * | 1984-11-15 | 1986-11-25 | Nastech Pharmaceutical Co., Inc. | Novel method of administering anti-nausea and anti-emetic pharmaceutical agents and novel dosage forms containing same |
| DE4131276B4 (de) * | 1990-09-28 | 2007-07-19 | Solvay Pharmaceuticals Gmbh | Peroral applizierbare Metoclopramidlösungen |
-
1996
- 1996-03-14 US US08/616,121 patent/US5760086A/en not_active Expired - Lifetime
-
1997
- 1997-03-13 CN CN97194427A patent/CN1217657A/zh active Pending
- 1997-03-13 NZ NZ331991A patent/NZ331991A/xx not_active IP Right Cessation
- 1997-03-13 IL IL12619997A patent/IL126199A/en not_active IP Right Cessation
- 1997-03-13 EE EE9800295A patent/EE03665B1/xx not_active IP Right Cessation
- 1997-03-13 ES ES97915060T patent/ES2357520T3/es not_active Expired - Lifetime
- 1997-03-13 PL PL97328940A patent/PL328940A1/xx unknown
- 1997-03-13 KR KR10-1998-0707237A patent/KR100420673B1/ko not_active Expired - Lifetime
- 1997-03-13 JP JP9532838A patent/JP2000507234A/ja not_active Ceased
- 1997-03-13 CA CA002248968A patent/CA2248968C/en not_active Expired - Lifetime
- 1997-03-13 YU YU40398A patent/YU40398A/sh unknown
- 1997-03-13 CZ CZ19982922A patent/CZ289797B6/cs not_active IP Right Cessation
- 1997-03-13 DE DE69740060T patent/DE69740060D1/de not_active Expired - Lifetime
- 1997-03-13 PT PT97915060T patent/PT891186E/pt unknown
- 1997-03-13 SK SK1259-98A patent/SK282695B6/sk unknown
- 1997-03-13 RU RU98118578/14A patent/RU2181588C2/ru active IP Right Revival
- 1997-03-13 DK DK97915060.4T patent/DK0891186T3/da active
- 1997-03-13 EP EP97915060A patent/EP0891186B1/en not_active Expired - Lifetime
- 1997-03-13 WO PCT/US1997/003974 patent/WO1997033573A1/en not_active Ceased
- 1997-03-13 AU AU22102/97A patent/AU707467B2/en not_active Ceased
- 1997-03-13 UA UA98105338A patent/UA57733C2/uk unknown
- 1997-03-13 AT AT97915060T patent/ATE489137T1/de active
-
1998
- 1998-09-14 NO NO984245A patent/NO984245L/no not_active Application Discontinuation
- 1998-09-18 BG BG102780A patent/BG102780A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ331991A (en) | 2000-04-28 |
| WO1997033573A1 (en) | 1997-09-18 |
| YU40398A (sh) | 2001-07-10 |
| RU2181588C2 (ru) | 2002-04-27 |
| BG102780A (en) | 2000-01-31 |
| CZ289797B6 (cs) | 2002-04-17 |
| PT891186E (pt) | 2011-02-25 |
| KR19990087763A (ko) | 1999-12-27 |
| DE69740060D1 (de) | 2011-01-05 |
| EP0891186B1 (en) | 2010-11-24 |
| AU707467B2 (en) | 1999-07-08 |
| AU2210297A (en) | 1997-10-01 |
| EE03665B1 (et) | 2002-04-15 |
| CN1217657A (zh) | 1999-05-26 |
| CA2248968C (en) | 2005-08-02 |
| PL328940A1 (en) | 1999-03-01 |
| NO984245L (no) | 1998-11-11 |
| CA2248968A1 (en) | 1997-09-18 |
| SK282695B6 (sk) | 2002-11-06 |
| UA57733C2 (uk) | 2003-07-15 |
| EE9800295A (et) | 1999-02-15 |
| ES2357520T3 (es) | 2011-04-27 |
| NO984245D0 (no) | 1998-09-14 |
| SK125998A3 (en) | 1999-03-12 |
| KR100420673B1 (ko) | 2004-07-23 |
| US5760086A (en) | 1998-06-02 |
| DK0891186T3 (da) | 2011-03-14 |
| EP0891186A4 (en) | 2004-03-31 |
| JP2000507234A (ja) | 2000-06-13 |
| IL126199A0 (en) | 1999-05-09 |
| CZ292298A3 (cs) | 1999-03-17 |
| EP0891186A1 (en) | 1999-01-20 |
| ATE489137T1 (de) | 2010-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5436272A (en) | Treatment of obesity | |
| US5801161A (en) | Pharmaceutical composition for the intranasal administration of hydroxocobalamin | |
| US5753712A (en) | Treatment of migraine headaches and formulations | |
| WO1992000743A1 (en) | Use of taurolidine and/or taurultam for the treatment of tumours | |
| AU707467B2 (en) | Nasal administration of agents for treatment of delayed onset emesis | |
| US5886012A (en) | Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers | |
| US5457132A (en) | Kit used in the treatment for hypertension using combination therapy involving exogenous calcium and calcium channel blockers | |
| US5661142A (en) | Anti-emetic composition | |
| US5925625A (en) | Pharmaceutical composition for the intranasal administration of hydroxocobalamin | |
| EP0938319A1 (en) | Pharmaceutical compositions containing alendronate and an agent promoting gastric emptying | |
| NL8105635A (nl) | Geneesmiddel met transplantaatafstotings- en/of immunologische ontstekingsremmende werking, alsmede werkwijze voor de remming van transplantaatafstoting en/of immunologische ontsteking. | |
| Kauffman et al. | Anaphylaxis upon switching lipid-containing amphotericin B formulations | |
| US4302452A (en) | Use of derivatives of 6α-methylprednisolone as an antiemetic | |
| US4522827A (en) | Method of treating acute pancreatitis with isometheptene | |
| MXPA98007474A (en) | Nasal administration of agents for the treatment of retard attack emesis | |
| US4663345A (en) | Etodolac for treatment of gout | |
| Stratigos et al. | Treatment of gonorrhoea with spectinomycin hydrochloride | |
| US6693100B1 (en) | Pharmaceutical compositions for treating psoriasis | |
| US4716177A (en) | Tolrestat for inhibition of weight gain | |
| US4701467A (en) | Tolrestat as anti-hypertensive agent | |
| HUP9902891A2 (hu) | Késleltetett kezdetű hányás kezelésére szolgáló metoklopranidtartalmú intranazális spray-készítmény | |
| WO2001019358A2 (en) | Use dexrazoxane for treating psoriasis | |
| WO2001089525A1 (de) | Kombination von cerivastatin mit ace inhibitoren und ihre verwendung in arzneimitteln | |
| SE8304818D0 (sv) | A medicine having anti-ulcer, spasmolytic and locally anesthetic effect | |
| HK1020008A (en) | Nasal administration of agents for treatment of delayed onset emesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| EXP | Patent expired |